A Study of a Melatonin Receptor Agonist to Prevent Migraine

Summary

The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia (trouble sleeping); however; ramelteon has not been approved for the prevention of migraines.

Timeline

Start

2008-04

Primary completion

2009-04

Completion

2010-09

Drugs

Indications